Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS...
Synonyms: 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-oneCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalPaltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth hormone (GH) and decreases the pro...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, whi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigationalPatients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesBenzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigationalBenzgalantamine is a prodrug of galantamine. Gastrointestinal adverse effects are the most frequently reported side effects in patients undergoing treatment with cholinesterase inhibitors, including galantamine, and are often a reason fo...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHydrastine
go.drugbank.com/drugs/DB19354ExperimentalCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 SubstratesSevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigationalDaraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma. It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bou...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesInterferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalHuman interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsInterferon beta-1b
go.drugbank.com/drugs/DB00068ApprovedInvestigationalHuman interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors